Celanese Corporation(NYSE: CE), a global technology and specialty materials company, today announced the launch of VitalDose™, an ethylene vinyl acetate (EVA) polymer-based excipient that facilitates drug makers’ efforts to develop and commercialize controlled-release pharmaceutical solutions.
VitalDose excipients are based on EVA polymers and offer a wide degree of flexibility in the design of transdermal, subcutaneous implant and mucosal insert dosage forms. VitalDose offers customizable release properties and the potential for new delivery routes to be used in the development of pharmaceutical product line extensions and new concepts.
Celanese的EVA Performance Polymers业务总经理Mark Murray说：“通过应用Celanese的VitalDose EVA赋形剂技术，我们正在帮助客户在充满复杂挑战的竞争市场中保持优势。”“随着竞争，尤其是来自仿制药的竞争，在制药行业的增长中，开发创新剂型的形式现在是保持该行业竞争优势的关键。为现有产品开发新的管理途径，或增强新开发但可溶的药物的生物利用度，是制药公司将其视为维持其产品特许经营成功的策略的重要选择。” Murray说。
“Celanese is investing in new and innovative resources to grow with the evolving pharmaceutical industry and is maximizing the value of that investment by building on its exceptional excipient technology with product development support and regulatory expertise to meet its customers’ specialized needs,” said Jon Mortimer, chief technology officer, Celanese Office of Strategic Growth. “VitalDose offers a wide degree of flexibility in the design of controlled release dosage solutions and is another example of how Celanese is committed to helping companies realize innovative growth opportunities through advanced product development.”
来源：http://www.celanese.com/